Pharsight

Zilretta generic

Zilretta is an injectable treatment for pain or inflammation owned by Pacira Pharms Inc. The drug contains the active ingredient, triamcinolone acetonide and was first authorized for market use on 06 October, 2017. Zilretta comes in a suspension, extended-release form for intra-articular usage.

When will Zilretta generic be available?

The generic versions of Zilretta are expected to be released after 04 August, 2031. This date marks the expiration of the last patent held by Pacira Pharms Inc. for Zilretta. It should be noted that this is not due to a Para IV filing.

Zilretta uses

Zilretta is primarily used in the treatment of pain and inflammation. Its active ingredient, triamcinolone acetonide, is a corticosteroid that helps to reduce these symptoms. The drug is delivered via an injectable controlled or sustained release formulation, enhancing its effectiveness.

Zilretta patent expiration

Zilretta holds two patents, both of which expire on 04 August, 2031. The patents, titled 'Corticosteroids for the treatment of joint pain,' protect the unique formulation and application of the drug. For more detailed information regarding the Zilretta generic and its patents, browse below. Below are the details of the patent:

Zilretta dosage

Want to ask something?